MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Rhythm Pharmaceuticals Inc

Închisă

SectorSănătate

89.28 0.13

Rezumat

Modificarea prețului

24h

Curent

Minim

87.32

Maxim

90

Indicatori cheie

By Trading Economics

Venit

-6.2M

-49M

Vânzări

-9.1M

33M

Marjă de profit

-151.352

Angajați

283

EBITDA

-9.5M

-47M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+14.74% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.8B

5.9B

Deschiderea anterioară

89.15

Închiderea anterioară

89.28

Sentimentul știrilor

By Acuity

50%

50%

154 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 iul. 2025, 23:41 UTC

Market Talk

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 iul. 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 iul. 2025, 23:05 UTC

Market Talk

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 iul. 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 iul. 2025, 21:36 UTC

Market Talk

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 iul. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

15 iul. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 iul. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

15 iul. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 iul. 2025, 20:07 UTC

Câștiguri

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 iul. 2025, 20:06 UTC

Market Talk

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 iul. 2025, 19:54 UTC

Market Talk

Global Equities Roundup: Market Talk

15 iul. 2025, 19:54 UTC

Market Talk

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 iul. 2025, 19:38 UTC

Market Talk

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 iul. 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 iul. 2025, 19:07 UTC

Market Talk

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 iul. 2025, 19:03 UTC

Market Talk

Gold Slips as Big Buyers Pull Back -- Market Talk

15 iul. 2025, 18:32 UTC

Achiziții, Fuziuni, Preluări

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 iul. 2025, 18:31 UTC

Achiziții, Fuziuni, Preluări

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 iul. 2025, 18:13 UTC

Market Talk

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 iul. 2025, 17:40 UTC

Market Talk

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 iul. 2025, 17:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 iul. 2025, 17:25 UTC

Achiziții, Fuziuni, Preluări

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 iul. 2025, 17:24 UTC

Market Talk

Dollar Gains Strength After Inflation Data -- Market Talk

15 iul. 2025, 16:49 UTC

Market Talk

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

15 iul. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 iul. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

15 iul. 2025, 15:42 UTC

Market Talk

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparație

Modificare preț

Rhythm Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

14.74% sus

Prognoză pe 12 luni

Medie 102.29 USD  14.74%

Maxim 130 USD

Minim 80 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRhythm Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

14

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

60 / 65.58Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

154 / 376 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.